
TY  - JOUR
TI  - Paediatrics
JO  - Journal of Gastroenterology and Hepatology
VL  - 27
IS  - s4
SN  - 0815-9319
UR  - https://doi.org/10.1111/j.1440-1746.2011.07251_11.x
DO  - doi:10.1111/j.1440-1746.2011.07251_11.x
SP  - 158
EP  - 160
PY  - 2012
ER  - 

TY  - JOUR
TI  - Cornea and External Disease
JO  - Clinical & Experimental Ophthalmology
VL  - 36
IS  - s1
SN  - 1442-6404
UR  - https://doi.org/10.1111/j.1442-9071.2008.01748.x
DO  - doi:10.1111/j.1442-9071.2008.01748.x
SP  - A136
EP  - A201
PY  - 2008
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Journal of Diabetes Investigation
JA  - J Diabetes Investig
VL  - 10
IS  - S1
SN  - 2040-1116
UR  - https://doi.org/10.1111/jdi.13033
DO  - doi:10.1111/jdi.13033
SP  - 24
EP  - 44
PY  - 2019
ER  - 

TY  - JOUR
TI  - ASBMR 29th Annual Meeting
JO  - Journal of Bone and Mineral Research
JA  - J Bone Miner Res
VL  - 22
IS  - S1
SN  - 0884-0431
UR  - https://doi.org/10.1002/jbmr.5650221409
DO  - doi:10.1002/jbmr.5650221409
SP  - s352
EP  - s401
PY  - 2007
ER  - 

TY  - JOUR
TI  - Oral Posters
JO  - Colorectal Disease
VL  - 13
IS  - s6
SN  - 1462-8910
UR  - https://doi.org/10.1111/j.1463-1318.2011.02705.x
DO  - doi:10.1111/j.1463-1318.2011.02705.x
SP  - 8
EP  - 15
PY  - 2011
ER  - 

TY  - JOUR
TI  - 43rd Congress of the International Society of Paediatric Oncology (SIOP) 2011 Auckland, New Zealand, 28thâ€“30th October, 2011, SIOP Abstracts
JO  - Pediatric Blood & Cancer
JA  - Pediatr. Blood Cancer
VL  - 57
IS  - 5
SN  - 1545-5009
UR  - https://doi.org/10.1002/pbc.23299
DO  - doi:10.1002/pbc.23299
SP  - 705
EP  - 897
PY  - 2011
ER  - 

TY  - JOUR
TI  - Tentative Schedule of Abstract Presentations, April 28 to May 1, 2007, Tampa Convention Center
JO  - Wound Repair and Regeneration
VL  - 15
IS  - 2
SN  - 1067-1927
UR  - https://doi.org/10.1111/j.1524-475X.2007.00217.x
DO  - doi:10.1111/j.1524-475X.2007.00217.x
SP  - A13
EP  - A54
PY  - 2007
ER  - 

TY  - JOUR
TI  - Posters
JO  - European Journal of Clinical Investigation
JA  - Eur J Clin Invest
VL  - 49
IS  - S1
SN  - 0014-2972
UR  - https://doi.org/10.1111/eci.13109
DO  - doi:10.1111/eci.13109
SP  - 101
EP  - 221
PY  - 2019
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Journal of Gastroenterology and Hepatology
JA  - Journal of Gastroenterology and Hepatology
VL  - 31
IS  - S3
SN  - 0815-9319
UR  - https://doi.org/10.1111/jgh.13540
DO  - doi:10.1111/jgh.13540
SP  - 7
EP  - 441
PY  - 2016
ER  - 

TY  - JOUR
TI  - Nautilus and Triton, 17:00-19:00
JO  - International Journal of Developmental Neuroscience
JA  - International Journal of Developmental Neuroscience
VL  - 26
IS  - 8
SN  - 0736-5748
UR  - https://doi.org/10.1016/j.ijdevneu.2008.09.050
DO  - doi:10.1016/j.ijdevneu.2008.09.050
SP  - 841
EP  - 866
PY  - 2008
ER  - 

TY  - JOUR
TI  - 2017 ACCP Annual Meeting
JO  - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
JA  - Pharmacotherapy
VL  - 37
IS  - 12
SN  - 0277-0008
UR  - https://doi.org/10.1002/phar.2052
DO  - doi:10.1002/phar.2052
SP  - e124
EP  - e238
PY  - 2017
ER  - 

AU  - Altun, Ersan
AU  - Semelka, Richard C.
C7  - pp. 63-72
TI  - Safety of MRI and CT
SN  - 9780470906255
UR  - https://doi.org/10.1002/9781118484852.ch3
DO  - doi:10.1002/9781118484852.ch3
SP  - 63-72
KW  - breast milk
KW  - cancer
KW  - CT
KW  - diagnostic imaging safety
KW  - Gadolinium-based contrast agents (GBCAs)
KW  - iodine-based contrast agents (IBCAs)
KW  - ionizing radiation
KW  - MRI
PY  - 2017
AB  - Summary Diagnostic imaging safety has garnered considerable interest in medical literature because of concerns of health risks attributable to imaging investigation. Perhaps the greatest concern is the likelihood of cancer development, secondary to the use of increasing numbers and exposures of medical radiation, especially resulting from the increasing use of multislice CT scanners. Additional health concerns are the toxicity of iodine-based contrast agents (IBCAs) that are used in CT, and gadolinium-based contrast agents (GBCAs) that are used in MRI. The literature on the excretion of GBCAs and IBCAs into breast milk, and the gastro-intestinal absorption of these agents from breast milk is very limited. A review of the literature, however, reveals important facts: less than 1% of the administered maternal dose of contrast agent is excreted into breast milk; and less than 1% of the contrast medium in breast milk ingested by an infant is absorbed from the gastro-intestinal tract.
ER  - 

TY  - JOUR
TI  - BOMSS abstracts 2018
JO  - BJS (British Journal of Surgery)
JA  - Br J Surg
VL  - 105
IS  - S4
SN  - 9780470906255
UR  - https://doi.org/10.1002/bjs.10918
DO  - doi:10.1002/bjs.10918
SP  - 5
EP  - 30
PY  - 2018
ER  - 

TY  - JOUR
TI  - TSANZ Abstracts
JO  - Respirology
VL  - 10
IS  - s1
SN  - 9780470906255
UR  - https://doi.org/10.1111/j.1440-1843.2005.00663.x-i1
DO  - doi:10.1111/j.1440-1843.2005.00663.x-i1
SP  - A8
EP  - A94
PY  - 2005
ER  - 

TY  - JOUR
TI  - Posters
JO  - Journal of Thrombosis and Haemostasis
VL  - 7
IS  - s2
SN  - 9780470906255
UR  - https://doi.org/10.1111/j.1538-7836.2009.03473_2.x
DO  - doi:10.1111/j.1538-7836.2009.03473_2.x
SP  - 317
EP  - 1168
PY  - 2009
ER  - 

TY  - JOUR
TI  - RESEARCH PODIUM ABSTRACTS
JO  - Value in Health
VL  - 13
IS  - 3
SN  - 9780470906255
UR  - https://doi.org/10.1111/j.1524-4733.2010.00722_1.x
DO  - doi:10.1111/j.1524-4733.2010.00722_1.x
SP  - A1
EP  - A13
PY  - 2010
ER  - 

TY  - JOUR
TI  - RESEARCH POSTER ABSTRACTS
JO  - Value in Health
VL  - 13
IS  - 3
SN  - 9780470906255
UR  - https://doi.org/10.1111/j.1524-4733.2010.00722_2.x
DO  - doi:10.1111/j.1524-4733.2010.00722_2.x
SP  - A13
EP  - A219
PY  - 2010
ER  - 

TY  - JOUR
AU  - Denysenko, Tetyana
AU  - Gennero, Luisa
AU  - Juenemann, Carola
AU  - Morra, Isabella
AU  - Masperi, Paolo
AU  - Ceroni, Vincenzo
AU  - Pragliola, Antonella
AU  - Ponzetto, Antonio
AU  - Melcarne, Antonio
TI  - Heterogeneous phenotype of human glioblastoma: In vitro study
JO  - Cell Biochemistry and Function
JA  - Cell Biochem Funct
VL  - 32
IS  - 2
SN  - 9780470906255
UR  - https://doi.org/10.1002/cbf.2988
DO  - doi:10.1002/cbf.2988
SP  - 164
EP  - 176
KW  - glioblastoma
KW  - cancer stem cells
KW  - CD133
KW  - hydroxyurea
KW  - glioblastoma subtypes
PY  - 2014
AB  - Glioblastomas (GBMs) are the most lethal primary brain tumours. Increasing evidence shows that brain tumours contain the population of stem cells, so-called cancer stem cells (CSCs). Stem cell marker CD133 was reported to identify CSC population in GBM. Further studies have indicated that CD133 negative cells exhibiting similar properties and are able to initiate the tumour, self-renew and undergo multilineage differentiation. GBM is a highly heterogeneous tumour and may contain different stem cell populations with different functional properties. We characterized five GBM cell lines, established from surgical samples, according to the marker expression, proliferation and differentiation potential. CD133 positive cell lines showed increased proliferation rate in neurosphere condition and marked differentiation potential towards neuronal lineages. Whereas two cell lines low-expressing CD133 marker showed mesenchymal properties in vitro, that is high proliferation rate in serum condition and differentiation in mesenchymal cell types. Further, we compared therapy resistance capacity of GBM cell lines treated with hydroxyurea. Our results suggest that CSC concept is more complex than it was believed before, and CD133 could not define entire stem cell population within GBM. At least two different subtypes of GBM CSCs exist, which may have different biological characteristics and imply different therapeutic strategies. Copyright ? 2013 John Wiley & Sons, Ltd.
ER  - 

TY  - JOUR
AU  - Yagi, Takahito
AU  - Nobuoka, Daisuke
AU  - Shinoura, Susumu
AU  - Umeda, Yuzo
AU  - Sato, Daisuke
AU  - Yoshida, Ryuichi
AU  - Utsumi, Masashi
AU  - Fuji, Tomokazu
AU  - Sadamori, Hiroshi
AU  - Fujiwara, Toshiyoshi
TI  - First successful case of simultaneous liver and kidney transplantation for patients with chronic liver and renal failure in Japan
JO  - Hepatology Research
JA  - Hepatol Res
VL  - 44
IS  - 3
SN  - 9780470906255
UR  - https://doi.org/10.1111/hepr.12122
DO  - doi:10.1111/hepr.12122
SP  - 358
EP  - 363
KW  - deceased donor
KW  - kidney transplantation
KW  - liver transplantation
KW  - living donor
KW  - retransplantation
KW  - simultaneous
PY  - 2014
AB  - Establishment of a preferential liver allocation rule for simultaneous liver and kidney transplantation (SLK) and revisions of laws regarding organ transplants from deceased donors have paved the way for SLK in Japan. Very few cases of SLK have been attempted in Japan, and no such recipients have survived for longer than 40 days. The present report describes a case of a 50-year-old woman who had undergone living donor liver transplantation at the age of 38 years for management of post-partum liver failure. After the first transplant surgery, she developed hepatic vein stenosis and severe hypersplenism requiring splenectomy. She was then initiated on hemodialysis (HD) due to the deterioration of renal function after insertion of a hepatic vein stent. She was listed as a candidate for SLK in 2011 because she required frequent plasma exchange for hepatic coma. When her Model for End-stage Liver Disease score reached 46, the new liver was donated 46 days after registration. The reduced trisegment liver and the kidney grafts were simultaneously transplanted under veno-venous bypass and intraoperative HD. The hepatic artery was reconstructed prior to portal reconstruction in order to shorten anhepatic time. Although she developed subcapsular bleeding caused by hepatic contusion on the next day, subsequent hemostasis was obtained by transcatheter embolization. Thereafter, her recovery was uneventful, except for mild rejection and renal tubular acidosis of the kidney graft. This case highlights the need to establish Japanese criteria for SLK.
ER  - 

TY  - JOUR
TI  - International Society of Paediatric Oncology, SIOP XXXVIII Congress Meeting: Contents and Abstracts
JO  - Pediatric Blood & Cancer
JA  - Pediatr. Blood Cancer
VL  - 47
IS  - 4
SN  - 9780470906255
UR  - https://doi.org/10.1002/pbc.21044
DO  - doi:10.1002/pbc.21044
SP  - 355
EP  - 532
PY  - 2006
ER  - 
